Comparing the Efficacy of Anti-secretory Versus Oral Immunoglobulins for Reducing the Episodes of Diarrhea in Children
Primary Purpose
Diarrhea
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Racecadotril
DiaResQ Children's Powder for Suspension
Sponsored by
About this trial
This is an interventional treatment trial for Diarrhea
Eligibility Criteria
Inclusion Criteria:
- Children 1-12 years both male and female visiting/admitted in Children Hospital PIMS with acute diarrhea of less than 15 days duration
Exclusion Criteria:
- Children requiring emergency resuscitation.
- Children having diarrhea of more than 15 days duration..
- Children with other comorbid conditions like heart, kidney and liver failure.
- Children with fructose intolerance, glucose malabsorption syndrome and saccharase isomaltase deficiency.
- Children allergic to egg or any of the contents.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Group A
Group B
Arm Description
Group A (GA) will receive anti secretory 1.5mg/kg/dose three doses per oral in 24 hours for 3 days along with oral rehydration
Group B (GB) will receive a single dose of bovine colostrum and egg solids as 7 g of dry powder reconstituted in 30 mL of water and taken orally once daily for 3 days along with oral rehydration
Outcomes
Primary Outcome Measures
frequency of diarrheal episodes
reduction in frequency of diarrheal episodes after administration of drug
Secondary Outcome Measures
Full Information
NCT ID
NCT04885049
First Posted
May 9, 2021
Last Updated
August 22, 2021
Sponsor
Shaheed Zulfiqar Ali Bhutto Medical University
1. Study Identification
Unique Protocol Identification Number
NCT04885049
Brief Title
Comparing the Efficacy of Anti-secretory Versus Oral Immunoglobulins for Reducing the Episodes of Diarrhea in Children
Official Title
A Randomized Controlled Trial Comparing the Efficacy of Anti Secretory and Oral Immunoglobulins Reducing the Episodes of Diarrhea in Children
Study Type
Interventional
2. Study Status
Record Verification Date
August 2021
Overall Recruitment Status
Unknown status
Study Start Date
September 1, 2021 (Anticipated)
Primary Completion Date
February 1, 2022 (Anticipated)
Study Completion Date
February 1, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Shaheed Zulfiqar Ali Bhutto Medical University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Children 1-12 years presenting/admitted with acute diarrhea will be enrolled in the study after taking informed consent from the parents. Patients will be randomly allocated to two equal groups. Group A (GA) will receive anti secretory 1.5mg/kg/dose, three doses in 24 hours along with oral rehydration, while Group B (GB) will receive a single dose of bovine immunoglobulins. Response to treatment will be assessed by recording the frequency of loose stools after 72 hrs. Data will be collected through a structured proforma.
Detailed Description
It is a randomized clinical trial that will be conducted at Children Hospital PIMS, Islamabad over the period of 6 months. Sample size is calculated using World Health Organization (WHO) calculator, keeping confidence level 95%, level of significance 5%, power of the test 80%,anticipated population proportion 1: 84%, anticipated population proportion 2: 93%, which turn out to be 30.Consecutive non probability sampling technique will be used. Children 1-12 years both male and female visiting/admitted in Children Hospital PIMS with acute diarrhea of less than 15 days duration will be enrolled in the study after taking informed consent from the parents. Children requiring emergency resuscitation, having chronic diarrhea i-e more than 15 days duration, having other comorbid conditions like heart, kidney and liver failure, having metabolic disorder and who are allergic to egg or any of the contents will be excluded from the study.
Child's name, age, sex will be recorded by the on duty doctor. Patients will be randomly allocated to two equal groups. Group A (GA) will receive anti secretory 1.5mg/kg/dose three doses per oral in 24 hours along with oral rehydration, while Group B (GB) will receive a single dose of bovine colostrum and egg solids as 7 g of dry powder reconstituted in 30 mL of water and taken orally once daily for 3 days along with oral rehydration. Response to treatment will be assessed by recording the reduction in frequency of diarrheal episodes after administration of drug and duration in which the diarrheal episodes were reduced. Data will be collected through a structured proforma.
All data will be analyzed using latest SPSS version. Quantitative variables such as age, time will be presented as means and standard deviations. Qualitative variables such as age groups, sex, recurrence of seizures and efficacy will be measured as frequency and percentages. Effect modifiers like age, gender will be controlled by stratification. Post stratification chi-square test will be applied keeping p value ≤0.05 as significant.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diarrhea
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Group A
Arm Type
Experimental
Arm Description
Group A (GA) will receive anti secretory 1.5mg/kg/dose three doses per oral in 24 hours for 3 days along with oral rehydration
Arm Title
Group B
Arm Type
Experimental
Arm Description
Group B (GB) will receive a single dose of bovine colostrum and egg solids as 7 g of dry powder reconstituted in 30 mL of water and taken orally once daily for 3 days along with oral rehydration
Intervention Type
Drug
Intervention Name(s)
Racecadotril
Intervention Description
Anti secretary
Intervention Type
Drug
Intervention Name(s)
DiaResQ Children's Powder for Suspension
Intervention Description
oral immunoglobulins
Primary Outcome Measure Information:
Title
frequency of diarrheal episodes
Description
reduction in frequency of diarrheal episodes after administration of drug
Time Frame
24 to 72 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Children 1-12 years both male and female visiting/admitted in Children Hospital PIMS with acute diarrhea of less than 15 days duration
Exclusion Criteria:
Children requiring emergency resuscitation.
Children having diarrhea of more than 15 days duration..
Children with other comorbid conditions like heart, kidney and liver failure.
Children with fructose intolerance, glucose malabsorption syndrome and saccharase isomaltase deficiency.
Children allergic to egg or any of the contents.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Nighat Haider, FCPS
Phone
+92519107695
Email
nighathaider@hotmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nighat Haider, FCPS
Organizational Affiliation
Shaheed Zulfiqar Ali Bhutto Medical University
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
If somebody wants the IPD they can email the principal investigator and it will be provided after the publication
IPD Sharing Time Frame
6 months after publication of data.
IPD Sharing Access Criteria
If somebody wants the IPD they can email the principal investigator and it will be provided
Learn more about this trial
Comparing the Efficacy of Anti-secretory Versus Oral Immunoglobulins for Reducing the Episodes of Diarrhea in Children
We'll reach out to this number within 24 hrs